Koers Guardion Health Sciences Inc Nasdaq
Aandelen
US40145Q2030
Farmaceutische producten
Omzet 2024 * | 13,45 mln. 12,39 mln. | Omzet 2025 * | 14,8 mln. 13,63 mln. | Marktkapitalisatie | 11,9 mln. 10,96 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -3 mln. -2,76 mln. | Nettowinst (verlies) 2025 * | -3 mln. -2,76 mln. | EV/omzet 2024 * | 0,88 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,8 x |
K/w-verhouding 2024 * |
-3,86
x | K/w-verhouding 2025 * |
-9,08
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 79,71% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jan Hall
CEO | Chief Executive Officer | - | 19-06-23 |
Chairman | 72 | 30-06-15 | |
Katie Cox
AUD | Comptroller/Controller/Auditor | - | 25-07-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 72 | 30-06-15 | |
Mark Goldstone
BRD | Director/Board Member | 60 | 01-06-15 |
Donald Gagliano
BRD | Director/Board Member | 71 | 09-04-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+37,78% | 723 mld. | |
+32,82% | 598 mld. | |
-3,51% | 364 mld. | |
+19,94% | 331 mld. | |
+5,14% | 288 mld. | |
+16,64% | 244 mld. | |
-4,13% | 208 mld. | |
+10,63% | 210 mld. | |
+9,32% | 169 mld. |